Role of NaV1.7 in postganglionic sympathetic nerve function in human and guinea‐pig arteries

Joyce S. Kim,Sonya Meeker,Fei Ru,Minh Tran,Tanja S. Zabka,David Hackos,Bradley J. Undem
DOI: https://doi.org/10.1113/jp286538
2024-05-16
The Journal of Physiology
Abstract:figure legend Blocking NaV1.7 pharmacologically demonstrated a profound impact on sympathetic adrenergic responses in both guinea‐pigs and human vascular smooth muscle, leading to either complete abolition or strong inhibition. These findings support the hypothesis that pharmacologically inhibiting NaV1.7 could potentially reduce sympathetic functions in specific vascular beds. ACh: acetylcholine, nACHRs: nicotinic acetylcholine receptor, NA: noradrenaline (norepinephrine), α: alpha‐1 adrenoreceptor. NaV1.7 plays a crucial role in inducing and conducting action potentials in pain‐transducing sensory nociceptor fibres, suggesting that NaV1.7 blockers could be effective non‐opioid analgesics. While SCN9A is expressed in both sensory and autonomic neurons, its functional role in the autonomic system remains less established. Our single neuron rt‐PCR analysis revealed that 82% of sympathetic neurons isolated from guinea‐pig stellate ganglia expressed NaV1.7 mRNA, with NaV1.3 being the only other tetrodotoxin‐sensitive channel expressed in approximately 50% of neurons. We investigated the role of NaV1.7 in conducting action potentials in postganglionic sympathetic nerves and in the sympathetic adrenergic contractions of blood vessels using selective NaV1.7 inhibitors. Two highly selective NaV1.7 blockers, GNE8493 and PF 05089771, significantly inhibited postganglionic compound action potentials by approximately 70% (P
neurosciences,physiology
What problem does this paper attempt to address?